PRECIGEN, INC. — Form 10-Q
Filed August 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Amendment No. 3 to the 2023 Omnibus Incentive Plan, effective April 20, 2026 (subject to shareholder approval at the 2026 Annual Meeting), increases the maximum shares available for issuance from 26M to 33M shares (+7M). The filing also includes a standard form Performance Stock Unit Agreement with performance milestones tied to Papzimeos revenue in fiscal 2026, vesting over 2027–2028, with threshold/target/maximum payouts at 50%/100%/200% (specific revenue targets redacted). No material operational or financial events are disclosed.
Why this rating
Share dilution is ongoing expense management; 7M shares ~3.2% of estimated outstanding. No business/product/revenue changes disclosed. Routine equity plan administration.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.